Acusphere Inc.

Sherri C. Oberg, a co-founder of Acusphere, has served as our President and Chief Executive Officer and one of our directors since our inception in 1993. Prior to joining Acusphere, Ms. Oberg was President and Chief Executive Officer of Neomorphics, Inc., a venture capital backed company focused on tissue engineering, from 1991 to 1992. Prior to joining Neomorphics, she was a venture capitalist at Aegis Venture Funds from 1988 to 1991, and at Inco Venture Capital Management from 1986 to 1988. Ms. Oberg is a member of the Board of Overseers of The Amos Tuck School at Dartmouth College. Ms. Oberg holds a B.A. from Dartmouth College and an M.B.A. from the Amos Tuck School of Business Administration.

Lawrence A. Gyenes has served as Senior Vice President, Chief Financial Officer and Secretary since October 2007 and as Treasurer since March 2008. From March 2007 to July 2007, Mr. Gyenes served as Chief Financial Officer of Zila, Inc. From March 2006 to February 2007, Mr. Gyenes provided independent healthcare financial consulting services primarily to investment management firms. From August 2004 to October 2005, Mr. Gyenes was Senior Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc. From July 2001 to July 2004, Mr. Gyenes was Chief Financial Officer of privately held Reliant Pharmaceuticals, Inc. From January 2001 to June 2001, Mr. Gyenes consulted on the divestiture of the DuPont Pharmaceuticals Company. Previously, Mr. Gyenes served as Chief Financial Officer of Rand McNally & Co., CompuServe Corporation and Helene Curtis, Inc. Mr. Gyenes spent 15 years in progressively more responsible positions with G. D. Searle & Co. completing his career there as Corporate Vice President, Finance responsible for the company's global finance and information technology functions. Mr. Gyenes has a B.S. in Accounting from the University of Illinois and an MBA from the University of Chicago.

Howard Bernstein, M.D., Ph.D. has served as Executive Vice President, Research and Development of the Company since February 2007, as Senior Vice President, Research and Development since January 2000 and as Vice President of Research and Development from 1994 to January 2000. Prior to joining the Company, Dr. Bernstein served as Vice President of Pharmaceutical Development at Alkermes, Inc. from 1992 to 1994 and as Vice President of Research at Enzytech Inc. from 1991 to 1992. Dr. Bernstein holds an M.D. from Harvard Medical School and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Mr. Slater has served as Senior Vice President, Operations at Acusphere since 2001. Prior to joining Acusphere, he was Vice President of Operations and Vice President of Quality Systems and Regulatory Affairs at Anika Therapeutics, Inc. Mr. Slater has also served as Vice President of Regulatory Affairs at Biogen, Inc., Director of Corporate Regulatory Affairs at Biogen S.A., an independent consultant to the biopharmaceutical industry, as well as Executive Vice President, Development Operations for ImmuLogic Pharmaceutical Corporation. While at Hoechst Pharmaceuticals he held various positions including Senior Manager, Medical Services. Mr. Slater holds a B.S. in Information Science from the Metropolitan University of Leeds, England.

Richard Walovitch, Ph.D. has served as Senior Vice President, Clinical Research of the Company since November 2005 and as Vice President, Clinical Research from March 1997 to November 2005. Prior to joining Acusphere, Dr. Walovitch was Vice President of Pre-clinical and Clinical Research at Epix Medical Inc. (formerly Metasyn) from 1993 to 1997 and the International Project Clinician at DuPont Merck Pharmaceutical Company from 1988 to 1993. Dr. Walovitch holds a B.S. in Biology and a Ph.D. in Pharmacology from the University of Illinois.

Dr. Langer has served as a scientific consultant and director since June 2002. Dr. Langer is currently the Chairman of the Company s Scientific Advisory Board. Dr. Langer is a co-founder of Sontra Medical, Inc. Since 1979, Dr. Langer has been Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. Dr. Langer is also currently a director of Momenta Pharmaceuticals, Inc., a biotechnology company developing drugs based on sugar sequencing technology, Boston Life Sciences, Inc., a company focused on research and development of therapeutic and diagnostic products, and Wyeth, a pharmaceutical and consumer healthcare products company. Dr. Langer received his B.S. from Cornell University in 1970 and his Ph.D. from MIT in 1974, both in chemical engineering.

Derek Lemke-von Ammon, has served as a director of the Company since 2002. Mr. Lemke-von Ammon is a General Partner at FTVentures. Previous to joining FTVentures Mr. Lemke-von Ammon was a Managing Partner for Thomas Weisel Capital Partners, a Director of Private Equity for Thomas Weisel Partners, and a member of the Firm's Executive Committee until December 2003. Prior to joining Thomas Weisel Capital Partners in 1998, Mr. Lemke-von Ammon was a Senior Managing Director and Director of Private Equity at Montgomery Securities from 1989 to 1998. Prior to joining Montgomery Securities, Mr. Lemke-von Ammon was a Vice President at Dain Bosworth Incorporated where he was employed from 1985 to 1989. He also worked as a corporate and securities attorney from 1983 to 1985 for Bogle & Gates in Seattle.

Michael H. Picard, MD, is the director of clinical echocardiography and a staff cardiologist at Boston 's Massachusetts General Hospital , an associate professor of medicine at Harvard Medical School and a past-president of the American Society of Echocardiography (ASE). He also serves on the National Board of Echocardiography and a member of the Imaging Council of the American College of Cardiology. He has published extensively on use of echocardiography and its new ultrasound technologies in coronary artery disease, valve disease and heart failure.

William I. Ramage, D. Phil., has served as an Executive Consultant at Acusphere since 2000 and as an Independent Business Development and Strategic Marketing Consultant to us from 1999 to 2000 and to other clients since 1998. Prior to Acusphere, Dr. Ramage was Vice President Business Development and Marketing at Molecular BioSystems from 1996 to 1998, and Vice President Business Development and Customer Services at DuPont Merck, a leader in nuclear imaging agents for myocardial perfusion imaging, from 1995 to 1996. Dr. Ramage holds a B.Sc. from the University of Glasgow and a D.Phil. from Oxford University.

Garen Bohlin, has served as one of our directors since 2005. Mr. Bohlin is the Chief Operating Officer for Sirtris Pharmaceuticals, Inc. in Cambridge, M.A. Previous to Sirtris, Mr. Bohlin served as President and CEO of Syntonix Pharmaceuticals, Inc. Prior to joining Syntonix, Mr. Bohlin was Executive Vice President of Genetics Institute where he was responsible for essentially all of the non-scientific areas that comprised approximately half of the then 1600 employees. Mr. Bohlin spent 14 years in executive management at Genetics Institute managing significant growth and playing a leading role in the closing of a broad range of financings. Prior Mr. Bohlin's tenure at Genetics Institute he spent 13 years at Arthur Andersen & Co. In addition to serving on Acusphere's Board, he is also a member of the Board of Directors of Targanta Pharmaceuticals, Inc.

Since July 2004, Mr. Greenacre has served as Chairman of Beijing Med-Pharm Corporation, a pharmaceutical company. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. From 1997 to 2001, Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1993 to 1997, Mr.

Sandra L. Fenwick, has served as one of our directors since 2004. Ms. Fenwick is Chief Operating Officer of the world-renowned Children's Hospital in Boston, Massachusetts. Prior to joining Children's Hospital in 1999, Ms. Fenwick was Senior Vice President of System Development for CareGroup, Inc. Before its merger with CareGroup, Ms. Fenwick served at Beth Israel Hospital for 20 years in various areas of increasing responsibility including Vice President and Deputy Director, Vice President of Clinical Services Planning and Development and Vice President of Network Development for Beth Israel Healthcare.